| Literature DB >> 34198338 |
Elham Bidar1,2,3, Stef Zeemering2,3, Martijn Gilbers2, Aaron Isaacs2,3, Sander Verheule2,3, Matthias D Zink2, Bart Maesen1,2,3, Sander Bramer4, Michal Kawczynski1,2,3, Isabelle C Van Gelder5, Harry J G M Crijns3,6, Jos G Maessen1,2,3, Ulrich Schotten2,3.
Abstract
AIMS: Postoperative atrial fibrillation (POAF) after cardiac surgery is an independent predictor of stroke and mortality late after discharge. We aimed to determine the burden and predictors of early (up to 5th postoperative day) and late (after 5th postoperative day) new-onset atrial fibrillation (AF) using implantable loop recorders (ILRs) in patients undergoing open chest cardiac surgery. METHODS ANDEntities:
Keywords: Atrial fibrillation substrate; Continuous rhythm monitoring; Implantable loop recorder; Postoperative atrial fibrillation
Mesh:
Year: 2021 PMID: 34198338 PMCID: PMC8651165 DOI: 10.1093/europace/euab136
Source DB: PubMed Journal: Europace ISSN: 1099-5129 Impact factor: 5.486
Baseline characteristics
| Clinical | |
|---|---|
| Age (years) | 65 ± 9.0 |
| BMI (kg/m2) | 27.5 ± 4.5 |
| RA volume (mL) | 51.9 ± 15.7 |
| LA volume (mL) | 79 ± 24.5 |
| LVEF (%) | 60 ± 5 |
| Creatinin (U/L) | 90.1 ± 21.2 |
| COPD | 11 (13.9%) |
| CHA2DS2 VASc | 2 ± 5 |
| CHF | 10 (12.7%) |
| Hypertension | 79 (100%) |
| Age >75/65–75 | 13 (16.5%)/23 (29.1%) |
| Diabetes | 16 (20.3%) |
| Stroke/TIA | 6 (7.6%) |
| Vascular disease | 15 (19.0%) |
| Sex | 20 female (25.3%) |
| Operative | |
| CABG | 57 (72.2%) |
| AVR ± CABG | 18 (22.8%) |
| MVR ± CABG | 4 (5.0%) |
| AoCCT (min) | 60 ± 25 |
| ICU-stay (days) | 1 (1–13) |
| Hospitalization (days) | 5 (3–53) |
| Preoperative medication | |
| β-blockers | 57 (72.2%) |
| ACE inhibitors | 27 (34.2%) |
| Statins | 67 (84.8%) |
AoCCT, aortic cross clamp time; AVR, aortic valve replacement; BMI, body mass index; CABG, coronary artery bypass graft; CHA2DS2VASc score, CHF, congestive heart failure defined as EF < 40% and/or hospitalization for acute heart failure/hypertension/age/diabetes/sex/vascular disease; LVEF, left ventricular ejection fraction; MVP, mitral valve repair/replacement; RA, right atrium.
Cross tabulation between early and late POAF
| No late POAF | Late POAF | Total | |
|---|---|---|---|
| No early POAF | 33 (42) | 19 (24) | 52 (66) |
| Early POAF | 9 (11) | 18 (23) | 27 (34) |
| 42 (53) | 37 (47) | 79 (100) |
X 2 6.5, N = 79, P = 0.01.
POAF, postoperative atrial fibrillation.
Clinical and electrophysiological characteristics; results of analysis of variance (ANOVA) of patients developing early and late POAF
| No POAF ( | POAF ( |
| No early POAF ( | Early POAF ( |
| No late POAF ( | Late POAF ( |
| |
|---|---|---|---|---|---|---|---|---|---|
| BMI | 28.0 | 27.1 | 0.55 | 28 | 27 | 0.84 | 27 | 28 | 0.78 |
| Age (years) | 61 | 68 | 0.01 | 63 | 70 | 0.002 | 62 | 69 | 0.02 |
| AoCCT (min) | 60 | 60 | 0.98 | 59 | 63 | 0.55 | 59 | 62 | 0.58 |
| CRP (mg/L) | 3.9 | 3.7 | 0.87 | 3.8 | 3.7 | 0.94 | 3.5 | 4.1 | 0.67 |
| CHA2DS2VASc | 2 | 3 | 0.01 | 2 | 3 | 0.001 | 2 | 2 | 0.14 |
| RA volume (mL) | 49 | 55 | 0.09 | 53 | 49 | 0.40 | 48 | 57 | 0.03 |
| RAVI (mL/m2) | 24 | 28 | 0.07 | 27 | 26 | 0.7 | 24 | 29 | 0.03 |
| LA volume (mL) | 76 | 74 | 0.8 | 78 | 69 | 0.2 | 73 | 77 | 0.5 |
| LAVI (mL/m2) | 38 | 38 | 0.9 | 39 | 35 | 0.3 | 33 | 31 | 0.7 |
| P duration (ms) | 114 | 112 | 0.66 | 114 | 110 | 0.27 | 111 | 114 | 0.36 |
| P dispersion | 40.6 | 40.7 | 0.97 | 41.9 | 38.0 | 0.5 | 39.7 | 41.8 | 0.67 |
| PR-time (ms) | 160.5 | 169.3 | 0.05 | 165.6 | 165.3 | 0.95 | 161 | 172 | 0.01 |
| P area (mm2) | 3.46 | 3.45 | 0.95 | 3.52 | 3.30 | 0.4 | 1.12 | 0.91 | 0.43 |
| P amplitude (mV) | 0.08 | 0.08 | 0.24 | 0.08 | 0.07 | 0.4 | 0.081 | 0.083 | 0.42 |
| P axis° | 43 | 41 | 0.7 | 41 | 44 | 0.5 | 43 | 41 | 0.7 |
AoCCT, aortic cross clamp time; BMI, body mass index; BT, breakthrough wave; CHA2DS2VASc score, CHF, congestive heart failure defined as EF < 40% and/or hospitalization for acute heart failure/hypertension/age/diabetes/sex/vascular disease; CRP, C-reactive protein; FI, fractionation index; LA, left atrium; LAVI, left atrial volume indexed for body surface area; P, P-wave; RA, right atrium; RAVI, right atrial volume indexed for body surface area.
Electrophysiological characteristics of epicardial mapping, results of analysis of variance (ANOVA)
| POAF ( | No POAF ( |
| Early POAF ( | No early POAF ( |
| Late POAF ( | No late POAF ( |
| |
|---|---|---|---|---|---|---|---|---|---|
| AFCL (ms) | 183 (±34) | 169 (±26) | 0.1 | 181 (±31) | 175 (±35) | 0.5 | 182 (±34) | 172 (±28) | 0.2 |
| CV (m/s) | 0.58 (±0.09) | 0.58 (±0.06) | 0.9 | 0.58 (±0.09) | 0.57 (±0.07) | 0.7 | 0.57 (±0.08) | 0.58 (±0.07) | 0.9 |
| BT/cycle | 1.2 (±0.6) | 1.0 (±0.5) | 0.2 | 1.3 (±0.6) | 1.1 (±0.6) | 0.1 | 1.3 (±0.6) | 1.0 (±0.5) | 0.1 |
| RA-FI | 2.1 (±0.9) | 1.7 (±0.7) | 0.08 | 2.5 (±0.8) | 1.7 (±0.7) | <0.001 | 2.0 (±0.8) | 1.9 (±0.8) | 0.8 |
| waves/cycle | 5.0 (±1.5) | 4.1 (±1.6) | 0.07 | 5.3 (±1.5) | 4.3 (±1.5) | 0.04 | 5.0 (±1.7) | 4.2 (±1.4) | 0.06 |
AFCL, atrial fibrillation cycle length; BT, breakthrough waves; CL, cycle length; CV, conduction velocity (m/s); FI, fractionation index; ms, milliseconds; POAF, postoperative atrial fibrillation; RA, right atrium.
Results of multivariate Cox-regression analysis in the late POAF prediction model (N = 79)
| □ | HR | 95% CI |
| |
|---|---|---|---|---|
| RAVI | 0.5 | 1.05 | 1.01–1.09 | 0.01 |
| Early POAF | 1.3 | 3.50 | 1.7–7.1 | 0.001 |
| PR time | 0.3 | 1.03 | 1.01–1.05 | 0.003 |
CI, confidence interval; HR, hazard ratio; POAF, postoperative atrial fibrillation; RAVI, right atrial volume indexed for body surface area.
Results of multivariate Cox-regression analysis in the late POAF after 3 months blanking period (N = 79)
| □ | HR | 95% CI |
| |
|---|---|---|---|---|
| Age | 0.06 | 1.1 | 1.00–1.13 | 0.05 |
| RA volume | 0.03 | 1.03 | 1.001–1.06 | 0.02 |
| Early POAF | 1.2 | 3.3 | 1.16–9.35 | 0.03 |
CI, confidence interval; HR, hazard ratio; POAF, postoperative atrial fibrillation; RA volume, right atrial volume.